Helicobacter pylori infection
Conditions
Interventions
Individuals who receive primary eradication treatment for H. pylori infection are taken Bioferumin R powder 3 g/day for two weeks from the first day of eradication treatmen.
Individuals who receive pr
Sponsors
Kobe University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Patient who was suspected for H. pylori infection and were positive for H. pylori in one of the following examination, urea breath test, H. pylori stool antigen test, H.pylori antibody test in the urine or in the blood, rapid urease test. (2) Patient who is expected an beneficial effect after H.pylori radication treatment. (3) Patients written consent from the person is obtained. (4) Patients without allergy to the use drugs.
Exclusion criteria
Exclusion criteria: (1) Patients who have already taken H. pylori eradication therapy before. (2) Patients who had taken any antibiotics or PPI within 4 weeks before the start day of the study. (3) Patients under 20 years. (4) Patients who had taken gastric cancer sugery before (except endoscopic surgery). (5) Patients with severe renal impairment, serious heart disease, or severe liver disease. (6) Patients with allergy to the use drugs. (7) In the cases the test doctor has determined the patient does not fit the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The occurrence of diarrea during H. pylori eradication therapy (day 0 to day 6) in biofermin R administration group and placebo group. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.Gut microflora change (alpha and beta divesity change) at day7, day 14 and pont of judgement after eradication therapy 2.Occurrence of side effect other than diarrhea 3.FSSG scal score before and after therapy 4.Serum diamine oxydase activity before and after therapy 5.Occurence of diarrhea after eradication therapy (between day 7 to day 13) | — |
Countries
Japan
Contacts
Public ContactJun Inoue
Kobe University Hospital Gastroenterology
Outcome results
None listed